CATALYST PHARMACEUTICALS INC (CPRX) Stock Fundamental Analysis
USA - NASDAQ:CPRX - US14888U1016 - Common Stock
21.34 USD
-0.1 (-0.47%)
21.4001 USD
+0.06 (+0.28%)
CPRX gets a fundamental rating of 8 out of 10. The analysis compared the fundamentals against 534 industry peers in the Biotechnology industry. Both the health and profitability get an excellent rating, making CPRX a very profitable company, without any liquidiy or solvency issues. CPRX has both an excellent growth and valuation score. This means it is growing and it is still cheap. This is a rare combination! With these ratings, CPRX could be worth investigating further for value and growth and quality investing!.
1. Profitability
1.1 Basic Checks
CPRX had positive earnings in the past year.
In the past year CPRX had a positive cash flow from operations.
Each year in the past 5 years CPRX has been profitable.
Each year in the past 5 years CPRX had a positive operating cash flow.
1.2 Ratios
CPRX has a Return On Assets of 21.47%. This is amongst the best in the industry. CPRX outperforms 97.00% of its industry peers.
CPRX's Return On Equity of 24.38% is amongst the best of the industry. CPRX outperforms 96.63% of its industry peers.
With an excellent Return On Invested Capital value of 21.45%, CPRX belongs to the best of the industry, outperforming 97.75% of the companies in the same industry.
Measured over the past 3 years, the Average Return On Invested Capital for CPRX is above the industry average of 15.38%.
The last Return On Invested Capital (21.45%) for CPRX is above the 3 year average (20.37%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 21.47% | ||
| ROE | 24.38% | ||
| ROIC | 21.45% |
ROA(3y)18.85%
ROA(5y)22.43%
ROE(3y)22.87%
ROE(5y)26.38%
ROIC(3y)20.37%
ROIC(5y)19.67%
1.3 Margins
CPRX has a Profit Margin of 37.36%. This is amongst the best in the industry. CPRX outperforms 97.38% of its industry peers.
In the last couple of years the Profit Margin of CPRX has remained more or less at the same level.
CPRX has a better Operating Margin (43.58%) than 99.06% of its industry peers.
In the last couple of years the Operating Margin of CPRX has grown nicely.
Looking at the Gross Margin, with a value of 85.78%, CPRX belongs to the top of the industry, outperforming 87.83% of the companies in the same industry.
In the last couple of years the Gross Margin of CPRX has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 43.58% | ||
| PM (TTM) | 37.36% | ||
| GM | 85.78% |
OM growth 3Y2.16%
OM growth 5Y5%
PM growth 3Y5.91%
PM growth 5Y1.34%
GM growth 3Y0.61%
GM growth 5Y0.11%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), CPRX is creating value.
CPRX has more shares outstanding than it did 1 year ago.
CPRX has more shares outstanding than it did 5 years ago.
There is no outstanding debt for CPRX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
CPRX has an Altman-Z score of 16.35. This indicates that CPRX is financially healthy and has little risk of bankruptcy at the moment.
CPRX has a better Altman-Z score (16.35) than 88.58% of its industry peers.
There is no outstanding debt for CPRX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 16.35 |
ROIC/WACC2.45
WACC8.75%
2.3 Liquidity
A Current Ratio of 6.71 indicates that CPRX has no problem at all paying its short term obligations.
The Current ratio of CPRX (6.71) is better than 67.79% of its industry peers.
CPRX has a Quick Ratio of 6.55. This indicates that CPRX is financially healthy and has no problem in meeting its short term obligations.
CPRX has a better Quick ratio (6.55) than 67.42% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 6.71 | ||
| Quick Ratio | 6.55 |
3. Growth
3.1 Past
CPRX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 205.56%, which is quite impressive.
The Earnings Per Share has been growing by 34.29% on average over the past years. This is a very strong growth
Looking at the last year, CPRX shows a very strong growth in Revenue. The Revenue has grown by 28.54%.
CPRX shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 36.89% yearly.
EPS 1Y (TTM)205.56%
EPS 3Y52.41%
EPS 5Y34.29%
EPS Q2Q%24.24%
Revenue 1Y (TTM)28.54%
Revenue growth 3Y51.72%
Revenue growth 5Y36.89%
Sales Q2Q%19.44%
3.2 Future
CPRX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 26.50% yearly.
CPRX is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 11.27% yearly.
EPS Next Y13.52%
EPS Next 2Y14.64%
EPS Next 3Y10.93%
EPS Next 5Y26.5%
Revenue Next Year16.1%
Revenue Next 2Y12.39%
Revenue Next 3Y11.29%
Revenue Next 5Y11.27%
3.3 Evolution
The estimated forward EPS growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
CPRX is valuated correctly with a Price/Earnings ratio of 12.93.
Compared to the rest of the industry, the Price/Earnings ratio of CPRX indicates a rather cheap valuation: CPRX is cheaper than 97.19% of the companies listed in the same industry.
The average S&P500 Price/Earnings ratio is at 26.51. CPRX is valued rather cheaply when compared to this.
CPRX is valuated correctly with a Price/Forward Earnings ratio of 12.39.
CPRX's Price/Forward Earnings ratio is rather cheap when compared to the industry. CPRX is cheaper than 96.82% of the companies in the same industry.
CPRX's Price/Forward Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 22.53.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 12.93 | ||
| Fwd PE | 12.39 |
4.2 Price Multiples
97.94% of the companies in the same industry are more expensive than CPRX, based on the Enterprise Value to EBITDA ratio.
Based on the Price/Free Cash Flow ratio, CPRX is valued cheaply inside the industry as 98.31% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 9.51 | ||
| EV/EBITDA | 7.01 |
4.3 Compensation for Growth
CPRX's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
CPRX has an outstanding profitability rating, which may justify a higher PE ratio.
PEG (NY)0.96
PEG (5Y)0.38
EPS Next 2Y14.64%
EPS Next 3Y10.93%
5. Dividend
5.1 Amount
No dividends for CPRX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
21.34
-0.1 (-0.47%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners85.12%
Inst Owner Change-0.01%
Ins Owners5.59%
Ins Owner Change1.17%
Market Cap2.61B
Revenue(TTM)558.50M
Net Income(TTM)208.66M
Analysts88.57
Price Target34.68 (62.51%)
Short Float %7.36%
Short Ratio5.65
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)16.95%
Min EPS beat(2)4.13%
Max EPS beat(2)29.76%
EPS beat(4)4
Avg EPS beat(4)18.54%
Min EPS beat(4)4.13%
Max EPS beat(4)29.76%
EPS beat(8)8
Avg EPS beat(8)15.48%
EPS beat(12)11
Avg EPS beat(12)12.83%
EPS beat(16)12
Avg EPS beat(16)7.88%
Revenue beat(2)2
Avg Revenue beat(2)3.81%
Min Revenue beat(2)2.19%
Max Revenue beat(2)5.44%
Revenue beat(4)4
Avg Revenue beat(4)3.37%
Min Revenue beat(4)2.19%
Max Revenue beat(4)5.44%
Revenue beat(8)7
Avg Revenue beat(8)2.76%
Revenue beat(12)11
Avg Revenue beat(12)3.19%
Revenue beat(16)13
Avg Revenue beat(16)2.7%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0.61%
EPS NQ rev (3m)-4.6%
EPS NY rev (1m)0.14%
EPS NY rev (3m)-0.14%
Revenue NQ rev (1m)0.02%
Revenue NQ rev (3m)-1.53%
Revenue NY rev (1m)0.06%
Revenue NY rev (3m)0.19%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 12.93 | ||
| Fwd PE | 12.39 | ||
| P/S | 4.68 | ||
| P/FCF | 9.51 | ||
| P/OCF | 9.49 | ||
| P/B | 3.05 | ||
| P/tB | 3.64 | ||
| EV/EBITDA | 7.01 |
EPS(TTM)1.65
EY7.73%
EPS(NY)1.72
Fwd EY8.07%
FCF(TTM)2.24
FCFY10.52%
OCF(TTM)2.25
OCFY10.53%
SpS4.56
BVpS6.99
TBVpS5.87
PEG (NY)0.96
PEG (5Y)0.38
Graham Number16.11
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 21.47% | ||
| ROE | 24.38% | ||
| ROCE | 28.34% | ||
| ROIC | 21.45% | ||
| ROICexc | 89.37% | ||
| ROICexgc | 270.38% | ||
| OM | 43.58% | ||
| PM (TTM) | 37.36% | ||
| GM | 85.78% | ||
| FCFM | 49.19% |
ROA(3y)18.85%
ROA(5y)22.43%
ROE(3y)22.87%
ROE(5y)26.38%
ROIC(3y)20.37%
ROIC(5y)19.67%
ROICexc(3y)162.63%
ROICexc(5y)159.51%
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)26.92%
ROCE(5y)25.99%
ROICexgc growth 3Y8.72%
ROICexgc growth 5YN/A
ROICexc growth 3Y-30.16%
ROICexc growth 5YN/A
OM growth 3Y2.16%
OM growth 5Y5%
PM growth 3Y5.91%
PM growth 5Y1.34%
GM growth 3Y0.61%
GM growth 5Y0.11%
F-Score6
Asset Turnover0.57
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 0.99% | ||
| Cap/Sales | 0.07% | ||
| Interest Coverage | 165.59 | ||
| Cash Conversion | 97.81% | ||
| Profit Quality | 131.65% | ||
| Current Ratio | 6.71 | ||
| Quick Ratio | 6.55 | ||
| Altman-Z | 16.35 |
F-Score6
WACC8.75%
ROIC/WACC2.45
Cap/Depr(3y)0.72%
Cap/Depr(5y)100.44%
Cap/Sales(3y)0.06%
Cap/Sales(5y)0.18%
Profit Quality(3y)162.12%
Profit Quality(5y)139.35%
High Growth Momentum
Growth
EPS 1Y (TTM)205.56%
EPS 3Y52.41%
EPS 5Y34.29%
EPS Q2Q%24.24%
EPS Next Y13.52%
EPS Next 2Y14.64%
EPS Next 3Y10.93%
EPS Next 5Y26.5%
Revenue 1Y (TTM)28.54%
Revenue growth 3Y51.72%
Revenue growth 5Y36.89%
Sales Q2Q%19.44%
Revenue Next Year16.1%
Revenue Next 2Y12.39%
Revenue Next 3Y11.29%
Revenue Next 5Y11.27%
EBIT growth 1Y183.49%
EBIT growth 3Y55%
EBIT growth 5Y43.74%
EBIT Next Year63.54%
EBIT Next 3Y23.99%
EBIT Next 5YN/A
FCF growth 1Y121.55%
FCF growth 3Y59.11%
FCF growth 5Y47.22%
OCF growth 1Y121.67%
OCF growth 3Y58.35%
OCF growth 5Y47.28%
CATALYST PHARMACEUTICALS INC / CPRX FAQ
What is the ChartMill fundamental rating of CATALYST PHARMACEUTICALS INC (CPRX) stock?
ChartMill assigns a fundamental rating of 8 / 10 to CPRX.
What is the valuation status of CATALYST PHARMACEUTICALS INC (CPRX) stock?
ChartMill assigns a valuation rating of 8 / 10 to CATALYST PHARMACEUTICALS INC (CPRX). This can be considered as Undervalued.
Can you provide the profitability details for CATALYST PHARMACEUTICALS INC?
CATALYST PHARMACEUTICALS INC (CPRX) has a profitability rating of 9 / 10.
What is the financial health of CATALYST PHARMACEUTICALS INC (CPRX) stock?
The financial health rating of CATALYST PHARMACEUTICALS INC (CPRX) is 8 / 10.